NPY1R and cancer: The fact that BIBO3304 is unable to cross the blood-brain barrier and thus cannot affect the central action of other NPY1R-mediated functions, such as stimulating appetite and reducing energy expenditure, represents a distinct advantage in a cancer setting, since PC progression is often associated with tissue wasting (63–65).